KineMed, Inc. and Roche have entered a collaboration to jointly validate KineMed’s translational KineMarker technology, which measures the on-mechanism activity of compounds in animals and humans. This technology helps to accelerate the translation of promising therapeutic agents into advanced clinical studies. The two companies will clinically validate its proprietary KineMarker of collagen synthesis, a therapeutic target underlying tissue fibrosis, in an undisclosed disease area. Da...